EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSFOG00015010418
Gene Symbol: CHRM3
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSFOG00015009102
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSFOG00015008755
Gene Symbol: CHRM4
3 Cross references
182 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSFOG00015019529
Gene Symbol: CHRM4
3 Cross references
182 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSSFOG00015017582
Gene Symbol: CHRM5
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSFOG00015003786
Gene Symbol: CHRNA3
1 Cross references
200 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSFOG00015006685
Gene Symbol: CHRNA3
3 Cross references
201 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSSFOG00015000746
Gene Symbol: CHRNA4
1 Cross references
136 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSSFOG00015020486
Gene Symbol: CHRNA4
3 Cross references
192 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSFOG00015021395
Gene Symbol: CHRNB2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSFOG00015009958
Gene Symbol: CHRNB2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSSFOG00015003753
Gene Symbol: CHRNB4
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).